Table 1.
Patient Baseline Characteristics in the Main Analysis of ≥1 Circulating Tumor Cell
| Characteristic | Group 1 (+ + +) n = 24 | Group 2 (+ ± ±) n = 54 | Group 3 (−) n = 48 |
|---|---|---|---|
| Age, median (range), years | 57.0 (27–71) | 56.0 (27–74) | 56.5 (31–82) |
| <65, n (%) | 15 (62.5) | 42 (77.8) | 32 (66.7) |
| ≥65, n (%) | 9 (37.5) | 12 (22.2) | 16 (33.3) |
| Baseline ECOG PS, n (%) | |||
| 0 | 15 (62.5) | 30 (55.6) | 31 (64.6) |
| 1 | 9 (37.5) | 24 (44.4) | 16 (33.3) |
| 2 | 0 | 0 | 1 (2.1) |
| Race, n (%) | |||
| White | 18 (75.0) | 49 (90.7) | 37 (77.1) |
| Black/African American | 4 (16.7) | 3 (5.6) | 7 (14.6) |
| Not collected or reported | 2 (8.3) | 2 (3.7) | 4 (8.3) |
| Region, n (%) | |||
| North America | 13 (54.2) | 33 (61.1) | 23 (47.9) |
| Western Europe | 11 (45.8) | 20 (37.0) | 25 (52.1) |
| Australia | 0 | 1 (1.9) | 0 |
| Disease-free interval, n (%) | |||
| ≤1 year | 7 (29.2) | 12 (22.2) | 14 (29.2) |
| >1 year | 17 (70.8) | 41 (75.9) | 34 (70.8) |
| Triple negative at primary diagnosis, n (%) | 17 (70.8) | 45 (83.3) | 35 (72.9) |
| Site of metastasis, n (%) | |||
| Bone | 12 (50.0) | 21 (38.9) | 13 (27.1) |
| Breast | 7 (29.2) | 18 (33.3) | 7 (14.6) |
| Liver | 9 (37.5) | 17 (31.5) | 10 (20.8) |
| Lung/thoracic | 11 (45.8) | 33 (61.1) | 35 (72.9) |
| Lymph node(s) | 18 (75.0) | 45 (83.3) | 28 (58.3) |
| Skin/soft tissue | 5 (20.8) | 10 (18.5) | 8 (16.7) |
| Other | 4 (16.7) | 9 (16.7) | 10 (20.8) |
| Abdomen/peritoneal | 2 (8.3) | 2 (3.7) | 0 |
| Prior taxane treatment, n (%) | 17 (70.8) | 29 (53.7) | 33 (68.8) |
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.